TipRanks
Advertisement
Advertisement

SNGX Stock Latest News

Soligenix Shareholders Approve Governance and Capital Changes
Company AnnouncementsSoligenix Shareholders Approve Governance and Capital Changes
9d ago
8K
SNGX
Soligenix Expands At-the-Market Equity Offering Capacity
PremiumCompany Announcements
Soligenix Expands At-the-Market Equity Offering Capacity
3M ago
8K
SNGX
Soligenix Halts HyBryte Program, Refocuses Pipeline Strategy
PremiumCompany Announcements
Soligenix Halts HyBryte Program, Refocuses Pipeline Strategy
4M ago
8K
SNGX
BARDA supporting development of Bundibugyo ebolavirus vaccine candidates
PremiumThe Fly
BARDA supporting development of Bundibugyo ebolavirus vaccine candidates
4M ago
GOVX
MRNA
Soligenix to apply for vaccine development funding for Bundibugyo Ebola vaccine
PremiumThe Fly
Soligenix to apply for vaccine development funding for Bundibugyo Ebola vaccine
4M ago
SNGX
Soligenix Expands At-The-Market Equity Financing Capacity
PremiumCompany AnnouncementsSoligenix Expands At-The-Market Equity Financing Capacity
4M ago
8K
SNGX
Soligenix reports Q1 EPS (28c) vs. (97c) last year
Premium
The Fly
Soligenix reports Q1 EPS (28c) vs. (97c) last year
5M ago
SNGX
Soligenix price target lowered to $1.50 from $10 at Alliance Global
Premium
The Fly
Soligenix price target lowered to $1.50 from $10 at Alliance Global
5M ago
SNGX
Soligenix announces interim results of Phase 3 trial of HyBryte in lymphoma
PremiumThe Fly
Soligenix announces interim results of Phase 3 trial of HyBryte in lymphoma
5M ago
SNGX
Soligenix Halts FLASH2 Trial, Explores Strategic Alternatives
PremiumCompany Announcements
Soligenix Halts FLASH2 Trial, Explores Strategic Alternatives
5M ago
8K
SNGX
Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach 
PremiumTipRanks Newswire
Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach 
5M ago
SNGX
Soligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status
PremiumTipRanks Newswire
Soligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status
5M ago
SNGX
Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results
PremiumTipRanks NewswireSoligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results
6M ago
SNGX
Soligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy 
Premium
TipRanks Newswire
Soligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy 
6M ago
SNGX
Soligenix’s HyBryte shows efficacy in T-cell lymphoma published trial
Premium
The Fly
Soligenix’s HyBryte shows efficacy in T-cell lymphoma published trial
6M ago
SNGX
Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results
PremiumTipRanks Newswire
Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results
6M ago
SNGX
SNGX Earnings this Week: How Will it Perform?
PremiumPre-Earnings
SNGX Earnings this Week: How Will it Perform?
6M ago
SNGX
Soligenix (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease
PremiumTipRanks Newswire
Soligenix (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease
6M ago
SNGX
Soligenix’s SGX945 granted European Orphan Drug Designation in Behcet’s Disease
PremiumThe Fly
Soligenix’s SGX945 granted European Orphan Drug Designation in Behcet’s Disease
6M ago
SNGX
Soligenix (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach
PremiumTipRanks NewswireSoligenix (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach
6M ago
SNGX
Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
Premium
TipRanks Newswire
Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
6M ago
SNGX
Soligenix (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation
Premium
TipRanks Newswire
Soligenix (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation
6M ago
SNGX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >